Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients
Open Access
- 15 January 2019
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 6 (2) , 355-363
Abstract
Objectives: Teriflunomide, a disease‐modifying treatment approved for multiple sclerosis (MS), inhibits reversibly dihydroorotate dehydrogenase, an enzyme involved in de novo pyrimidine biosynthesis and down‐regulates proliferation of activated lymphocytes. We aimed to study the impact of this drug in the lymphocyte profiles of MS patients.Methods: Fifty‐five patients with relapsing‐remitting MS who initiated teriflunomide treatment were included in the study. We studied peripheral blood mononuclear cells obtained before and 6 months after treatment initiation and explored effector, memory, and regulatory cells by flow cytometry. Wilcoxon matched pair tests were used to assess differences between basal and 6 months after treatment results. P‐values were corrected with Bonferroni test.Results: When explored T and B cell subsets, we observed a decrease in the percentages of terminally differentiated CD4+ T cells (P = 0.001) and plasmablasts (P < 0.0001) after 6 months of treatment. These results were confirmed with the total cell number. When studied immunomodulatory cells, we observed a clear increase of monocytes expressing programmed death‐ligand 1 (PD‐L1) (P = 0.005), which correlated negatively with all effector CD8+ T cell subsets. We also observed an increase in the percentage of CD8+ T cells (P = 0.028) and monocytes (P = 0.04) producing IL‐10.Conclusions: Teriflunomide induces a specific reduction in effector T and B cells that have shown to play a role in MS course and an increase in immunomodulatory cells. Particularly, this drug induces the expression of PD‐L1, a molecule involved in tolerance to autoantigens, which can contribute to inhibit the abnormal immune response taking place in MS.Keywords
Funding Information
- Instituto de Salud Carlos III (FIS-PI15/00513, RD16/0015/0001)
- Ministerio de Economía y Competitividad
This publication has 24 references indexed in Scilit:
- PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomasNature Reviews Clinical Oncology, 2016
- Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseasesExpert Review of Clinical Pharmacology, 2015
- Teriflunomide (Aubagio®) for the treatment of multiple sclerosisExperimental Neurology, 2014
- Teriflunomide and Its Mechanism of Action in Multiple SclerosisDrugs, 2014
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Neurology, 2014
- The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitroJournal of Neuroimmunology, 2013
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialMultiple Sclerosis Journal, 2013
- Magnetic resonance imaging outcomes from a phase III trial of teriflunomideMultiple Sclerosis Journal, 2013
- Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosisMultiple Sclerosis Journal, 2012
- PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2European Journal of Immunology, 2002